Researchers report that once-weekly treatment with islatravir plus lenacapavir (ISL+LEN) in virologically suppressed adults with HIV has safely maintained high rates of virologic suppression through 48 weeks. The… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
